NEW YORK--(BUSINESS WIRE)--AiCure, a leading AI and advanced data analytics company that monitors patient behavior and enables remote patient engagement in clinical trials, is sponsoring the 14th Annual DPHARM® where it will unveil its groundbreaking H.Code platform.
H.Code is a new kind of clinical trial technology that blends computer vision, app-based communication tools, and predictive analytics to help site teams better understand and anticipate participant behavior during trials. In addition to addressing adherence, H.Code’s tools can identify and develop digital assessments that link behavior with disease and treatment outcomes, opening up new possibilities for precision medicine.
AiCure CEO, Ed Ikeguchi, will also deliver a speaking session at the conference on Wednesday, September 18, at 2:35 PM. The session, “From Chaos to Clarity: Simplifying Trial Participation with a Single Platform,” will explore how a single technology platform can simplify trials for participants, sites and sponsors, reducing the need for multiple patient-facing technologies by seamlessly integrating trial protocol into participants’ daily habits.
“DPHARM is an exciting event for AiCure, and we are thrilled to be a sponsor this year,” said Ikeguchi. “We can’t wait to introduce H.Code and demonstrate how it revolutionizes patient engagement. I look forward to sharing insights on how a single platform can enhance the trial experience for everyone involved.”
DPHARM attendees can learn more about H.Code and how it fits into their studies by visiting AiCure at Booth #46.
AiCure also announced the promotion of Josh Wilson to Chief Operating Officer (COO). In his new role, Josh will oversee all product management and operational aspects of the company, driving strategic initiatives that enhance AiCure's mission to improve clinical trials and the patient experience through innovative AI-powered solutions.
Josh Wilson joined AiCure as Senior Vice President of Operations in 2022, bringing over two decades of experience from leading roles at CROs including Syneos Health and INC Research. His extensive background in data management, technology implementation, and operational strategy has been instrumental in advancing AiCure's operational capabilities and enhancing the delivery of its platform and site services.
“Josh has demonstrated exceptional leadership and a deep understanding of our operational needs,” said AiCure CEO, Ed Ikeguchi. “His promotion to COO reflects our confidence in his ability to guide AiCure through its next phase of growth and innovation.”
About AiCure
AiCure is a leading AI and advanced data analytics company deploying H.Code, a patient engagement platform that reinvents the clinical trial experience for participants using AI-assisted dosing and compliance tools, seamless app-based communication, and comprehensive operational site services. Extend the reach of your clinical team non-intrusively with an all-in-one technology that makes clinical trials more accessible for participants and more rewarding for your study. To learn more, visit www.aicure.com.
